← back to search

C Colette

Montpellier Business School · FR
Area of research
Endocrinology, Diabetes and Metabolism · Physiology
Research interest
Research interests include Diabetes Management and Research, Diabetes Treatment and Management, Diabetes, Cardiovascular Risks, and Lipoproteins, and Diet and metabolism studies.
h-index
37
citations
8,914
works
280
NIH funding
primary concept
Medicine
email

Recent publications

Glycemic variability and iatrogenic hypoglycemia: how to resolve
Diabetes Research and Clinical Practice 2025cited by 3position: middledoi
Should glycaemic variability and times spent in levels 1 and 2 hypoglycaemia be revised downward in type 1 diabetes treated with advanced systems of insulin delivery?
Diabetes Obesity and Metabolism 2025cited by 1position: middledoi
Prevent hypoglycaemia when using automated insulin delivery systems in type 1 diabetes requires near normal glycaemic variability
Diabetes & Metabolism 2024cited by 5position: middledoi
Key indices of glycaemic variability for application in diabetes clinical practice
Diabetes & Metabolism 2023cited by 26position: middledoi
HbA1c variability and diabetes complications: assessment and implications
Diabetes & Metabolism 2022cited by 10position: middledoi
Below Which Threshold of Glycemic Variability Is There a Minimal Risk of Hypoglycemia in People with Type 2 Diabetes?
Diabetes Technology & Therapeutics 2022cited by 8position: middledoi
Three Key Indices in Clinical Practice to Better Comprehend the Postprandial and Basal Glucose Contributions in Type 2 Diabetes
Diabetes Technology & Therapeutics 2022cited by 1position: middledoi
Glycaemic variabilities: Key questions in pursuit of clarity
Diabetes & Metabolism 2021cited by 15position: middledoi
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Médecine des Maladies Métaboliques 2021cited by 1position: middledoi
Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée
Médecine des Maladies Métaboliques 2021cited by 0position: middledoi
Review of methods for detecting glycemic disorders
Diabetes Research and Clinical Practice 2020cited by 187position: middledoi
Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?
Diabetes Care 2020cited by 58position: middledoi
Application of medium-term metrics for assessing glucose homoeostasis: Usefulness, strengths and weaknesses
Diabetes & Metabolism 2020cited by 11position: middledoi
Number Needed-to-Treat (NNT): Is it a necessary marker of therapeutic efficiency?
Diabetes & Metabolism 2020cited by 6position: middledoi
Glucocentric risk factors for macrovascular complications in diabetes: Glucose ‘legacy’ and ‘variability’-what we see, know and try to comprehend
Diabetes & Metabolism 2019cited by 29position: middledoi
Calibration free continuous glucose monitoring (CGM) devices: Weighing up the benefits and limitations
Diabetes & Metabolism 2019cited by 10position: middledoi
Comment on Echouffo-Tcheugui et al. Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study. Diabetes Care 2019;42:486–493
Diabetes Care 2019cited by 3position: middledoi
The application of simple metrics in the assessment of glycaemic variability
Diabetes & Metabolism 2018cited by 106position: middledoi
La variabilité glycémique : l’évaluation de son impact passe par des index de mesure et des recommandations simples
Médecine des Maladies Métaboliques 2018cited by 4position: middledoi
Glucose variability: Do we have to revisit the profusion of definitions to avoid confusion?
Diabetes & Metabolism 2017cited by 14position: middledoi
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Diabetes Care 2016cited by 381position: middledoi
Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
Reviews in Endocrine and Metabolic Disorders 2016cited by 29position: middledoi
Residual dysglycemia when at target HbA1c of 7% (53mmol/mol) in persons with type 2 diabetes
Diabetes Research and Clinical Practice 2014cited by 34position: middledoi
“Mild dysglycemia” in type 2 diabetes: to be neglected or not?
Journal of Diabetes and its Complications 2014cited by 28position: middledoi
The dawn phenomenon in type 2 diabetes: How to assess it in clinical practice?
Diabetes & Metabolism 2014cited by 26position: middledoi
Response to Comment on Monnier et al. Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes: Is This of Concern? Diabetes Care 2013;36:4057–4062
Diabetes Care 2014cited by 0position: middledoi
Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes
Diabetes Care 2013cited by 104position: middledoi
Insulin and atherosclerosis: How are they related?
Diabetes & Metabolism 2013cited by 52position: middledoi
Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Diabetes & Metabolism 2013cited by 21position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David R. Owens · Swansea University26 papers (2013–2025)Louis Monnier · Montpellier Business School23 papers (2013–2025)S. Dejager · Novartis (Switzerland)7 papers (2013–2016)Fabrice Bonnet · Hôpital Saint-André5 papers (2020–2023) · 5 papers (2013–2021)Éric Renard · Université de Limoges4 papers (2016–2023) · 3 papers (2024–2025) · 3 papers (2016–2025)Anne Wojtusciszyn · Clinton Foundation2 papers (2016–2020) · 2 papers (2024–2025) · 2 papers (2024–2025)David Owens · Swansea University2 papers (2024–2025)Oliver Schnell · WEK Tierarzt1 papers (2013–2013) · 1 papers (2019–2019) · 1 papers (2013–2013) · 1 papers (2019–2019)